Aquestive Therapeutics (AQST) FCF Margin (2017 - 2026)
Aquestive Therapeutics (AQST) recorded quarterly FCF Margin of 102.85% in Q1 2026, down 467.83% quarter-over-quarter from 27.96% in Q4 2025, and up 16704.0% on a YoY basis from N/an in Q1 2025.
Aquestive Therapeutics (AQST) FCF Margin (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' FCF Margin history runs 10 years deep, the most recent figure standing at 102.85% for Q1 2026.
- In Q1 2026, FCF Margin rose 16704.0% year-over-year to 102.85%; the TTM figure through Mar 2026 stood at 665.02% (down 57459.0% YoY), while the FY2025 annual figure was 5649.68%, down 558728.0% from the prior year.
- FCF Margin was 102.85% for Q1 2026 at Aquestive Therapeutics, down from 27.96% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 79.16% in Q1 2023 to a low of 269.9% in Q1 2025.
- Historically, FCF Margin has averaged 55.39% across 5 years, with a median of 65.95% in 2023.
- The sharpest annual moves came in 2023 and 2025: FCF Margin surged 19804 bps in 2023, then plunged 18350 bps in 2025.
- A 5-year view of FCF Margin shows it stood at 78.54% in 2022, then sank by 148 bps to 37.54% in 2023, then sank by 46 bps to 54.81% in 2024, then soared by 151 bps to 27.96% in 2025, then tumbled by 468 bps to 102.85% in 2026.
- The last three FCF Margin figures came in at 102.85% (Q1 2026), 27.96% (Q4 2025), and 101.84% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -5.22% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 12.86% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 46.39% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 16.78% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -2.77% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -429.96% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 13.24% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 32.62% |
| 10 | Aquestive Therapeutics | 488.60 Mn | 377.87 Mn | 10.98 Mn | -102.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -102.85% |
| Dec 31, 2025 | 27.96% |
| Sep 30, 2025 | -101.84% |
| Jun 30, 2025 | -78.60% |
| Mar 31, 2025 | -269.90% |
| Dec 31, 2024 | -54.81% |
| Sep 30, 2024 | -88.79% |
| Jun 30, 2024 | -34.71% |
| Mar 31, 2024 | -86.39% |
| Dec 31, 2023 | -37.54% |
| Sep 30, 2023 | -19.21% |
| Jun 30, 2023 | -65.95% |
| Mar 31, 2023 | 79.16% |
| Dec 31, 2022 | 78.54% |
| Sep 30, 2022 | 22.61% |
| Jun 30, 2022 | -90.49% |
| Mar 31, 2022 | -118.88% |
| Dec 31, 2021 | -77.58% |
| Sep 30, 2021 | -68.85% |
| Jun 30, 2021 | -97.50% |